Has Ismail Tarkhan received payments from drug or device companies?

Yes. Drug and device makers reported $11,954 in general payments to Ismail Tarkhan across 397 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ismail Tarkhan did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ismail Tarkhan come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ismail Tarkhan

Internal Medicine · Milford, CTNPI 1902848609

Payments from drug & device makers

$11,954in general payments, 2019–2025

Across 397 payments — averaging $30.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$2K
Boehringer Ingelheim$2K
Novo Nordisk$1K
Merck$1K
GSK$946
Amgen$905
plus $4K from 19 others

$16,905in research payments, 2019–2025

Across 16 payments — averaging $1056.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novo Nordisk AS$17K

What the payments were for

Food & beverage$11,898100%
Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	58	$2,482
Boehringer Ingelheim	31	$1,606
Novo Nordisk	42	$1,208
Merck	39	$1,067
GSK	32	$946
Amgen	35	$905
Lilly USA, LLC	32	$734
Amarin Pharma, Inc.	29	$614
Novartis	19	$436
Arbor Pharmaceuticals, Inc.	34	$397
AbbVie(2 entities)	12	$331
Sanofi	2	$250
Medtronic(2 entities)	2	$222
Sanofi-aventis U.S. LLC	7	$141
Johnson & Johnson	2	$139
Bayer	1	$125
Currax Pharmaceuticals LLC	7	$114
Pfizer	3	$61
Mylan Specialty L.p.	2	$47
Eisai Inc.	3	$37
Novo Nordisk AS	1	$30
Indivior Inc.	1	$23
Genentech USA, Inc.	1	$14
Kowa Pharmaceuticals America, Inc.	1	$14
Nalpropion Pharmaceuticals LLC	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,954 in reported general payments places this provider in the 90th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut →

Other internal medicine in Milford

Steven SaundersMilford$49K
Gary SpectorMilford$32K
Joseph SouferWaterbury$21.5M
David RadinStamford$7M
Steven RyderWestport$3.9M
Nancy BrownNew Haven$2.8M
Charles MontanoCromwell$2.8M
Arthur DecillisMadison$1M
Michelle MallitzTrumbull$971K
Allen HellerWoodbridge$758K

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →